commercial agreement

Speciality chemicals business, Croda International, has agreed a new commercial arrangement with UK-based biopharmaceutical company, SiSaf. Read more


UK developer of cell-based therapeutics, ReNeuron Group, has signed an exclusivity agreement with a US-based specialty pharma company in connection with the potential out-licensing of its hRPC retinal stem cell technology and therapeutic programmes. Read more


Patients in England will now have immediate access to the new multiple sclerosis (MS) treatment, cladribine tablets (Mavenclad), thanks to a commercial agreement between the manufacturer, Merck, and NHS England that has been announced today. Read more